As the in-silico study has become an important tool to search the new drugs in the concurrent era with towering acceptance and accuracy, it is executed in our research for unearthing the effective cancer drugs. To say more, breast cancer has accounted for the serious diseases for both men and women although few research outputs have been obtained on breast cancer that is not an adequate amount to ascertain new drugs. Due to this gap, the virtual screening, In-silico study, provides the ability to design and select by quickly identifying anticancer compounds with desirable drug-like properties. A total of nine 2-aryloxazoline derivatives were chosen, and In-silico was studied as a potential anticancer agent with the comparison of seven Food and Drug Administration (FDA) approved breast cancer drugs. These compounds were subjected to computational ADME and Lipinski analysis, as well as molecular docking and molecular dynamics simulations calculations against a variety of therapeutic targets involved in cell proliferation (PDB ID: 3TJM, 3ERT, 4OAR, 2J6M). An in-silico docking study reveals that ligands Hit-4, Hit-6, and Hit-8 had the highest docking scores of -10.3 kcal/mole − 10.3 kcal/mole, and − 10.2 kcal/mole towards Fatty Acid Synthase. The ligands had docking scores better than the standard anti-breast cancer drug gefitinib (− 5.3 kcal/mole). Our studies show the significance of pharmaceutical researchers in designing and developing new anticancer breast cancer drugs.